Home » Newsletters » BioWorld

BioWorld

July 22, 1994

View Archived Issues

GLAXO, BIOCHEM START PHASE III OF HBV DRUG

OTHER NEWS TO NOTE

APPOINTMENTS AND ADVANCEMENTS

HUMAN GENOME SCIENCES SIGNS 20 NEW PACTS WITH RESEARCH INSTITUTES

GENETICS INSTITUTE TO GET $20M FROM WYETH-AYERST

CELLCOR RAISES $5.25M TO CONTINUE CLINICAL TRIALS

U.S., U.K. BIOTECHNOLOGY ASSOCIATIONS FORGE LINKS

LARGEST U.K.-U.S. DEAL CELLTECH, MERCK PACK TO DEVELOP ASTHMA DRUG

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026